{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T03:36:50Z","timestamp":1779334610774,"version":"3.51.4"},"reference-count":30,"publisher":"American Association for Cancer Research (AACR)","issue":"2","license":[{"start":{"date-parts":[[2023,2,21]],"date-time":"2023-02-21T00:00:00Z","timestamp":1676937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018289","name":"Shinnihon Foundation of Advanced Medical Treatment Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100018507","name":"Japan Medical Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100018507","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001691","name":"MEXT | Japan Society for the Promotion of Science","doi-asserted-by":"crossref","award":["21K16245"],"award-info":[{"award-number":["21K16245"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100017517","name":"Ohara Pharmaceuticals","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017517","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,2,21]]},"abstract":"<jats:p>The standard treatment for elderly patients with acute myeloid leukemia (AML) is venetoclax (Ven), a BCL-2\u2013selective inhibitor, combined with hypomethylating agents (HMA) such as azacitidine or decitabine. This regimen results in low toxicity, high response rates, and potentially durable remission; however, because of low oral bioavailability, these conventional HMAs must be administered intravenously or subcutaneously. A combination of oral HMAs and Ven would provide a therapeutic advantage over parenteral administration of drugs and improve quality of life by reducing the number of hospital visits. Previously, we showed the promising oral bioavailability and antileukemia effects of a new HMA, OR2100 (OR21). Here, we investigated the efficacy and underlying mechanism of OR21 when used in combination with Ven to treat AML. OR21\/Ven showed synergistic antileukemia effects in vitro, and significantly prolonged survival without increasing toxicity in a human leukemia xenograft mice model. RNA sequencing following combination therapy revealed downregulation of VAMP7, which is involved in autophagic maintenance of mitochondrial homeostasis. Combination therapy led to accumulation of reactive oxygen species, leading to increased apoptosis. The data suggest that the combination of OR21 plus Ven is a promising candidate oral therapy for AML.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Significance:<\/jats:title>\n                    <jats:p>The standard treatment for elderly patients with AML is Ven combined with HMAs. OR21, a new oral HMA plus Ven showed synergistic antileukemia effects in vitro and vivo, suggesting that the combination of OR2100 plus Ven is a promising candidate oral therapy for AML.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1158\/2767-9764.crc-22-0259","type":"journal-article","created":{"date-parts":[[2023,2,8]],"date-time":"2023-02-08T09:24:30Z","timestamp":1675848270000},"page":"297-308","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Combination of a New Oral Demethylating Agent, OR2100, and Venetoclax for Treatment of Acute Myeloid Leukemia"],"prefix":"10.1158","volume":"3","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7346-4864","authenticated-orcid":true,"given":"Kazuharu","family":"Kamachi","sequence":"first","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan."},{"name":"2Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5034-3699","authenticated-orcid":true,"given":"Hiroshi","family":"Ureshino","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan."},{"name":"2Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan."},{"name":"3Department of Hematology and Oncology, Research Institute for Radiation Biology and Medicine, Hiroshima University, Hiroshima, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4166-4781","authenticated-orcid":true,"given":"Tatsuro","family":"Watanabe","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-3662","authenticated-orcid":true,"given":"Nao","family":"Yoshida-Sakai","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5909-9303","authenticated-orcid":true,"given":"Yuki","family":"Fukuda-Kurahashi","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan."},{"name":"4OHARA Pharmaceutical Co., Ltd, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9476-3161","authenticated-orcid":true,"given":"Kazunori","family":"Kawasoe","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9083-1200","authenticated-orcid":true,"given":"Toshimi","family":"Hoshiko","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5905-7843","authenticated-orcid":true,"given":"Yuta","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6136-9037","authenticated-orcid":true,"given":"Yuki","family":"Kurahashi","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan."},{"name":"4OHARA Pharmaceutical Co., Ltd, Tokyo, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1717-6208","authenticated-orcid":true,"given":"Shinya","family":"Kimura","sequence":"additional","affiliation":[{"name":"1Department of Drug Discovery and Biomedical Sciences, Faculty of Medicine, Saga University, Saga, Japan."},{"name":"2Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1086","published-online":{"date-parts":[[2023,2,21]]},"reference":[{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(18)31041-9","article-title":"Acute myeloid leukaemia","volume":"392","author":"Short","year":"2018","journal-title":"Lancet"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"2358","DOI":"10.1182\/blood-2010-03-273243","article-title":"Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSGAML201 study","volume":"117","author":"Ohtake","year":"2011","journal-title":"Blood"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/bloodadvances.2021005538","article-title":"Venetoclax and azacitidine compared with induction chemotherapy for newly diagnosed patients with acute myeloid leukemia","volume":"5","author":"Cherry","year":"2021","journal-title":"Blood Adv"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","author":"Garcia-Manero","year":"2020","journal-title":"Blood"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1038\/s41375-021-01218-0","article-title":"Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies","volume":"35","author":"Stomper","year":"2021","journal-title":"Leukemia"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1200\/JCO.2010.34.4226","article-title":"Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia","volume":"29","author":"Garcia-Manero","year":"2011","journal-title":"J Clin Oncol"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1182\/blood.2019003084","article-title":"Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100","volume":"136","author":"Watanabe","year":"2020","journal-title":"Blood"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1158\/1535-7163.MCT-20-1125","article-title":"Silylation of deoxynucleotide analog yields an orally available drug with antileukemia effects","volume":"20","author":"Ureshino","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.canlet.2021.11.032","article-title":"Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia","volume":"526","author":"Kamachi","year":"2022","journal-title":"Cancer Lett"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1080\/19466315.2018.1437071","article-title":"Evaluation of drug combination effect using a Bliss independence dose-response surface model","volume":"10","author":"Liu","year":"2018","journal-title":"Stat Biopharm Res"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","author":"DiNardo","year":"2020","journal-title":"Blood"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1007\/s00277-012-1537-8","article-title":"Concomitant inhibition of DNA methyltransferase and BCL-2 protein function synergistically induce mitochondrial apoptosis in acute myelogenous leukemia cells","volume":"91","author":"Tsao","year":"2012","journal-title":"Ann Hematol"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41408-018-0165-5","article-title":"Superior efficacy of cotreatment with BET protein inhibitor and BCL2 or MCL1 inhibitor against AML blast progenitor cells","volume":"9","author":"Fiskus","year":"2019","journal-title":"Blood Cancer J"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/nature19830","article-title":"The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models","volume":"538","author":"Kotschy","year":"2016","journal-title":"Nature"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.febslet.2007.01.072","article-title":"The cytosolic ribonuclease inhibitor contributes to intracellular redox homeostasis","volume":"581","author":"Monti","year":"2007","journal-title":"FEBS Lett"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.2337\/db15-1207","article-title":"VAMP7 regulates autophagy to maintain mitochondrial homeostasis and to control insulin secretion in pancreatic \u03b2-cells","volume":"65","author":"Aoyagi","year":"2016","journal-title":"Diabetes"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/cdd.2014.150","article-title":"Oxidative stress and autophagy: the clash between damage and metabolic needs","volume":"22","author":"Filomeni","year":"2015","journal-title":"Cell Death Differ"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1038\/cdd.2012.81","article-title":"The pathways of mitophagy for quality control and clearance of mitochondria","volume":"20","author":"Ashrafi","year":"2013","journal-title":"Cell Death Differ"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"2526","DOI":"10.1056\/NEJMoa2004444","article-title":"Oral azacitidine maintenance therapy for acute myeloid leukemia in first remission","volume":"383","author":"Wei","year":"2020","journal-title":"N Engl J Med"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1158\/2159-8290.CD-19-0710","article-title":"Monocytic subclones confer resistance to venetoclax-based therapy in patients with acute myeloid leukemia","volume":"10","author":"Pei","year":"2020","journal-title":"Cancer Discov"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41419-020-02867-2","article-title":"Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition","volume":"11","author":"Roca-Portoles","year":"2020","journal-title":"Cell Death Dis"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"8860","DOI":"10.1074\/jbc.M611777200","article-title":"Inhibition of mitochondrial respiration as a source of adaphostin-induced reactive oxygen species and cytotoxicity","volume":"282","author":"Le","year":"2007","journal-title":"J Biol Chem"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"493","DOI":"10.3390\/cells8050493","article-title":"Mitophagy in cancer: a tale of adaptation","volume":"8","author":"Vara-Perez","year":"2019","journal-title":"Cells"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"20210016","DOI":"10.1515\/jib-2021-0016","article-title":"Predicting the possible effect of miR-203a-3p and miR-29a-3p on DNMT3B and GAS7 genes expression","volume":"19","author":"Ali","year":"2021","journal-title":"J Integr Bioinform"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41419-022-04540-2","article-title":"The EMT-induced lncRNA NR2F1-AS1 positively modulates NR2F1 expression and drives gastric cancer via miR-29a-3p\/VAMP7 axis","volume":"13","author":"Li","year":"2022","journal-title":"Cell Death Dis"},{"key":"2023022114004211100_","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1002\/ijc.33901","article-title":"Adult T-cell leukemia-lymphoma acquires resistance to DNA demethylating agents through dysregulation of enzymes involved in pyrimidine metabolism","volume":"150","author":"Yoshida-Sakai","year":"2022","journal-title":"Int J Cancer"}],"container-title":["Cancer Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/doi\/10.1158\/2767-9764.CRC-22-0259\/3268365\/crc-22-0259.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/2\/297\/3270826\/crc-22-0259.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article-pdf\/3\/2\/297\/3270826\/crc-22-0259.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T10:40:21Z","timestamp":1679654421000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerrescommun\/article\/3\/2\/297\/716657\/Combination-of-a-New-Oral-Demethylating-Agent"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,21]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2,21]]}},"URL":"https:\/\/doi.org\/10.1158\/2767-9764.crc-22-0259","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2767-9764.22546515.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551193.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.c.6551193","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546509.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546506.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546521.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546524.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546503.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546521","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546512.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546527","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546518.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546515","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546503","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546533","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546509","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546500.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546527.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546530","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546533.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546518","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546536.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546506","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546530.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546536","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546524","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546512","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2767-9764.22546500","asserted-by":"object"}]},"ISSN":["2767-9764"],"issn-type":[{"value":"2767-9764","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,2,21]]}}}